DexCom, Inc.
General ticker "DXCM" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $30.4B (TTM average)
DexCom, Inc. follows the US Stock Market performance with the rate: 5.1%.
Estimated limits based on current volatility of 1.2%: low 71.16$, high 72.91$
Factors to consider:
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Total employees count: 10300 (+7.3%) as of 2024
- US accounted for 71.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Economic downturns and volatility, Pricing pressures, Public health crises, Regulatory and compliance, Supply chain disruptions
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [46.48$, 80.67$]
- 2026-12-31 to 2027-12-31 estimated range: [51.14$, 86.11$]
Financial Metrics affecting the DXCM estimates:
- Negative: with PPE of 32.0 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 19.56 > 18.38
- Positive: Inventory ratio change, % of 0.06 <= 0.80
- Positive: Return on assets ratio (scaled to [-100,100]) of 11.65 > 6.11
- Positive: Investing cash flow per share per price, % of 2.06 > -0.63
- Positive: 0.01 < Operating cash flow per share per price, % of 5.53
- Positive: 42.68 < Shareholder equity ratio, % of 43.31 <= 64.29
Short-term DXCM quotes
Relationship graph
Long-term DXCM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $3,622.30MM | $4,033.00MM | $4,662.00MM |
| Operating Expenses | $3,024.60MM | $3,433.00MM | $3,750.20MM |
| Operating Income | $597.70MM | $600.00MM | $911.80MM |
| Non-Operating Income | $112.70MM | $109.00MM | $176.60MM |
| R&D Expense | $505.80MM | $552.40MM | $599.10MM |
| Income(Loss) | $710.40MM | $709.00MM | $1,088.40MM |
| Taxes | $168.90MM | $132.80MM | $252.10MM |
| Profit(Loss)* | $541.50MM | $576.20MM | $836.30MM |
| Stockholders Equity | $2,068.60MM | $2,102.60MM | $2,746.00MM |
| Inventory | $559.60MM | $542.60MM | $629.10MM |
| Assets | $6,264.50MM | $6,484.50MM | $6,339.90MM |
| Operating Cash Flow | $748.50MM | $989.50MM | $1,440.70MM |
| Capital expenditure | $236.60MM | $358.80MM | $363.50MM |
| Investing Cash Flow | $-507.20MM | $-207.50MM | $536.00MM |
| Financing Cash Flow | $-318.60MM | $-734.80MM | $-1,686.40MM |
| Earnings Per Share** | $1.40 | $1.42 | $2.14 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.